CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

EpiVax lance des modèles optimisés par l'IA pour la prédiction de l'immunogénicité

Positive
AI Analysis

Summary

EpiVax announced new AI-optimized features for ISPRI, its in silico platform for immunogenicity risk assessment. The announcement represents a routine product update to an existing computational platform.

Importance:3/10
Sentiment:
0.50
AI/machine learningimmunogenicity predictionplatform technologyISPRI

Read the original article

Published by PR Newswire Biotech on September 3, 2026 5:20 AM

Read Original